Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AN4035 + cetuximab
- Development stage
- Phase 1
- Lead developer
- Adlai Nortye
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AN4035 + cetuximab is an investigational combination therapy being evaluated for the treatment of advanced or metastatic solid tumors harboring RAS mutations and expressing CEACAM5. AN4035 is a novel antibody-drug conjugate (ADC) developed by Adlai Nortye, featuring a monoclonal antibody targeting Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5) conjugated to a proprietary pan-RAS(ON) inhibitor payload via a hydrophilic, enzyme-cleavable linker. Cetuximab is a chimeric monoclonal antibody that inhibits the Epidermal Growth Factor Receptor (EGFR). The combination strategy leverages the mechanistic complementarity of inhibiting EGFR upstream and RAS downstream, aiming to enhance pathway suppression and overcome therapeutic resistance in RAS-mutated cancers while minimizing systemic toxicity through targeted delivery.
- Other names
- AN4035 + EGFR inhibitor
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)EGFR (Epidermal growth factor receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)HRAS (H-Ras protein)
Beyond the preview
Go deeper on AN4035 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AN4035 + cetuximab.